How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

24,136 results for

Epilepsy Resources

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome

of non-drop seizures improving the quality of life of the siblings of people with Lennox–Gastaut syndrome. When taking both the uncertainties and the uncaptured benefits into account, cannabidiol is considered an appropriate use of NHS resources, and is recommended as an option for treating Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice (...) –Gastaut syndrome treatment pathway is consistent with NICE's clinical guideline on epilepsies: diagnosis and management. The guideline recommends starting treatment with sodium valproate and, if seizures are not adequately controlled, adding lamotrigine. They added that they would consider trying other antiepileptic drugs if sodium valproate and lamotrigine together do not adequately control seizures. The committee was aware that the marketing authorisation for cannabidiol is for use as an adjuvant

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

2. Cannabidiol with clobazam for treating seizures associated with Dravet syndrome

seizures reducing the duration of convulsive seizures improving the quality of life of the siblings of people with Dravet syndrome. When taking both the uncertainties and the uncaptured benefits into account, cannabidiol is Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 4 of 25considered an appropriate use of NHS resources (...) having fewer nights with seizures, when there is a higher risk of sudden unexpected death in epilepsy. The patient and carer expert considered that reducing the duration of convulsive seizures and the frequency of other seizure types would improve the quality of life of people with Dravet syndrome. The committee concluded that there is an unmet need for treatments that reduce the number and duration of convulsive seizures, and that patients and their carers would value a new treatment option

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

3. Gynecologic Management of Adolescents and Young Women With Seizure Disorders

with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients 2 years of age and older . General Contraceptive Considerations Adolescents with seizure disorders require ongoing education about potential adverse pregnancy outcomes and the most effective contraceptive options. Ideally, education should begin in early adolescence and continue throughout a patient’s reproductive lifespan because antiepileptic drugs, contraceptive needs, and desire for pregnancy may (...) 2011;52:199–211. Article Locations: Cummings LN, Giudice L, Morrell MJ. Ovulatory function in epilepsy. Epilepsia 1995;36:355–9. Article Locations: Tauboll E, Sveberg L, Svalheim S. Interactions between hormones and epilepsy. Seizure 2015;28:3–11. Article Locations: Morrell MJ, Hayes FJ, Sluss PM, Adams JM, Bhatt M, Ozkara C, et al. Hyperandrogenism, ovulatory dysfunction, and polycystic ovary syndrome with valproate versus lamotrigine. Ann Neurol 2008;64:200–11. Article Locations: Joffe H, Cohen LS

2020 American College of Obstetricians and Gynecologists

4. Duration of Anti-convulsant Therapy for Acute Symptomatic Seizure in Acute Encephalitis Syndrome

Enrollment : 60 participants Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: Whether 4 weeks anti-epileptic drug is as efficacious as 12 weeks anti-epileptic drug therapy for Acute Encephalitis syndrome Masking: None (Open Label) Masking Description: Open label study Primary Purpose: Treatment Official Title: Comparison of 4 Weeks Versus 12 Weeks Anti-convulsant Therapy for Acute Symptomatic Seizure in Children With Acute Encephalitis Syndrome- Open Label (...) Duration of Anti-convulsant Therapy for Acute Symptomatic Seizure in Acute Encephalitis Syndrome Duration of Anti-convulsant Therapy for Acute Symptomatic Seizure in Acute Encephalitis Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one

2017 Clinical Trials

5. Project UPLIFT for Psychogenic Non-Epileptic Seizures

Years to 65 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: History of psychogenic non-epileptic seizures, confirmed by study investigator. Literate Reliable telephone access Exclusion Criteria: Dual diagnosis of PNES with epilepsy. Presence of serious mental illness that will impair ability to participate. Presence of active suicidal ideation at baseline with intention to act. Severe mental disability or estimated intelligent (...) : No Studies a U.S. FDA-regulated Device Product: No Keywords provided by Lindsay M. Schommer, Dartmouth-Hitchcock Medical Center: PNES UPLIFT Depression Mindfulness CBT Managing Epilepsy Well (MEW) Network Psychogenic Seizures Non-Epileptic Seizures Additional relevant MeSH terms: Layout table for MeSH terms Depression Seizures Behavioral Symptoms Neurologic Manifestations Nervous System Diseases Signs and Symptoms

2017 Clinical Trials

6. A Study of Levetiracetam as Monotherapy or Adjunctive Treatment of Partial Seizures in Pediatric Epileptic Subjects Ranging From 1 Month to Less Than 4 Years of Age

of Levetiracetam as Monotherapy or Adjunctive Treatment of Partial Seizures in Pediatric Epileptic Subjects Ranging From 1 Month to Less Than 4 Years of Age Actual Study Start Date : November 30, 2017 Estimated Primary Completion Date : January 2022 Estimated Study Completion Date : January 2022 Resource links provided by the National Library of Medicine related topics: related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Levetiracetam Subjects aged 1 month to <6 (...) A Study of Levetiracetam as Monotherapy or Adjunctive Treatment of Partial Seizures in Pediatric Epileptic Subjects Ranging From 1 Month to Less Than 4 Years of Age A Study of Levetiracetam as Monotherapy or Adjunctive Treatment of Partial Seizures in Pediatric Epileptic Subjects Ranging From 1 Month to Less Than 4 Years of Age - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x

2017 Clinical Trials

7. Development of an Epileptic Seizure Detection Algorithm by Continuous Analysis of the Electrocardiogram

: NCT03369522 Recruitment Status : Recruiting First Posted : December 12, 2017 Last Update Posted : May 8, 2018 See Sponsor: University Hospital, Lille Information provided by (Responsible Party): University Hospital, Lille Study Details Study Description Go to Brief Summary: The aim of our project is to develop an epileptic seizure detection algorithm based on the the continuous analysis of the Electrocardiogram Condition or disease Seizures Epilepsy Electrocardiography Detailed Description: In a first (...) : Observational Estimated Enrollment : 200 participants Observational Model: Cohort Time Perspective: Prospective Official Title: Development of an Epileptic Seizure Detection Algorithm by Continuous Analysis of the Electrocardiogram Actual Study Start Date : December 13, 2017 Estimated Primary Completion Date : January 2020 Estimated Study Completion Date : January 2020 Resource links provided by the National Library of Medicine related topics: related topics: Groups and Cohorts Go to Group/Cohort

2017 Clinical Trials

8. An Exploratory Trial Using sEMG to Differentiate PNES From Epileptic Seizures

/treatment Non-Epileptic Seizure Motor Seizure Epilepsy Device: Brain Sentinel Monitoring and Alerting System Study Design Go to Layout table for study information Study Type : Observational Estimated Enrollment : 40 participants Observational Model: Cohort Time Perspective: Prospective Official Title: An Exploratory Trial Using sEMG to Differentiate PNES From Epileptic Seizures Actual Study Start Date : September 1, 2017 Estimated Primary Completion Date : May 1, 2019 Estimated Study Completion Date (...) : May 1, 2019 Resource links provided by the National Library of Medicine related topics: related topics: Groups and Cohorts Go to Group/Cohort Intervention/treatment PNES Cohort Participants who experience a non-epileptic event with upper extremity motor involvement, while enrolled in the trial Device: Brain Sentinel Monitoring and Alerting System The Brain Sentinel Monitoring and Alerting System is indicated for use as an adjunct to seizure monitoring in adults in the home or healthcare facilities

2017 Clinical Trials

9. A Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II)

A Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II) A Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x (...) × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated

2017 Clinical Trials

10. Impact of SPEAC® System Data on Therapeutic Decisions Related to Convulsive Seizure Patients With a New Diagnosis

care. Masking: None (Open Label) Primary Purpose: Diagnostic Official Title: Impact of SPEAC® System Data on Therapeutic Decisions Related to Convulsive Seizure Patients With a New Diagnosis Actual Study Start Date : November 2, 2018 Estimated Primary Completion Date : November 2019 Estimated Study Completion Date : November 2024 Resource links provided by the National Library of Medicine related topics: related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: Treatment (...) Impact of SPEAC® System Data on Therapeutic Decisions Related to Convulsive Seizure Patients With a New Diagnosis Impact of SPEAC® System Data on Therapeutic Decisions Related to Convulsive Seizure Patients With a New Diagnosis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

2018 Clinical Trials

11. Impact of SPEAC® System Data on Therapeutic Decisions Related to Convulsive Seizure Patients With a Recent Non-diagnostic EMU Visit

Purpose: Diagnostic Official Title: Impact of SPEAC® System Data on Therapeutic Decisions Related to Convulsive Seizure Patients With a Recent Non-diagnostic EMU Visit Estimated Study Start Date : November 2018 Estimated Primary Completion Date : October 2019 Estimated Study Completion Date : October 2024 Resource links provided by the National Library of Medicine related topics: related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: Treatment Group SPEAC System Device (...) Impact of SPEAC® System Data on Therapeutic Decisions Related to Convulsive Seizure Patients With a Recent Non-diagnostic EMU Visit Impact of SPEAC® System Data on Therapeutic Decisions Related to Convulsive Seizure Patients With a Recent Non-diagnostic EMU Visit - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You

2018 Clinical Trials

12. Impact of SPEAC® System Data on Therapeutic Decisions Related to Convulsive Seizure Patient's Refractory to AEDs

Title: Impact of SPEAC® System Data on Therapeutic Decisions Related to Convulsive Seizure Patient's Refractory to AEDs Estimated Study Start Date : November 2018 Estimated Primary Completion Date : October 2019 Estimated Study Completion Date : October 2024 Resource links provided by the National Library of Medicine related topics: related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: Treatment Group SPEAC System Device: SPEAC System Surface Electromyography (sEMG (...) Impact of SPEAC® System Data on Therapeutic Decisions Related to Convulsive Seizure Patient's Refractory to AEDs Impact of SPEAC® System Data on Therapeutic Decisions Related to Convulsive Seizure Patient's Refractory to AEDs - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2018 Clinical Trials

13. Seizure frequency, healthcare resource utilisation and mortality in childhood epilepsy: a retrospective cohort study using the THIN database. Full Text available with Trip Pro

Seizure frequency, healthcare resource utilisation and mortality in childhood epilepsy: a retrospective cohort study using the THIN database. To understand the association of seizure frequency with healthcare resource utilisation (HCRU) and mortality in UK children with epilepsy (CWE).Retrospective cohort study.Routinely collected data in primary care from The Health Improvement Network UK database.CWE ≥1 and<18 years of age with a record of seizure frequency were included in mortality analyses (...) visits and increased direct HCRU costs (24%). 11 patients died during 12 490 patient-years follow-up. The unadjusted HR of mortality per higher category of seizure frequency was 2.56 (95% CI: 1.52 to 4.31). Adjustment for age and number of prescribed anti-epileptic drugs at index attenuated this estimate to 2.11 (95% CI: 1.24 to 3.60).Higher seizure frequency is associated with greater HCRU and mortality in CWE in the UK. Improvement in seizure control may potentially lead to better patient outcomes

2019 Archives of Disease in Childhood

14. A Comparison of Parenteral Phenobarbital vs. Parenteral Phenytoin as Second-Line Management for Pediatric Convulsive Status Epilepticus in a Resource-Limited Setting. Full Text available with Trip Pro

A Comparison of Parenteral Phenobarbital vs. Parenteral Phenytoin as Second-Line Management for Pediatric Convulsive Status Epilepticus in a Resource-Limited Setting. Introduction: Pediatric convulsive status epilepticus (CSE) which is refractory to first-line benzodiazepines is a significant clinical challenge, especially within resource-limited countries. Parenteral phenobarbital is widely used in Africa as second-line agent for pediatric CSE, however evidence to support its use is limited (...) -to-treat analysis was performed with the investigators blinded to the treatment arms. The primary outcome measure was the success of terminating CSE. Secondary outcomes included the need for admission to the pediatric intensive care unit (PICU) and breakthrough seizures during the admission. In addition, local epidemiological data was collected on the burden of pediatric CSE. Results: Between 2015 and 2018, 193 episodes of CSE from 111 children were enrolled in the study of which 144 met the study

2019 Frontiers in neurology Controlled trial quality: predicted high

15. Partial seizures in children and young people with epilepsy: zonisamide as adjunctive therapy

in line with the Guideline on Clinical Investigation of Medicinal Products in the Treatment of Epileptic Disorders. It also stated that inclusion and exclusion criteria, participants included in the study and the choice of primary and secondary end points were considered appropriate for the indication being applied for. Partial seizures in children and young people with epilepsy: zonisamide as adjunctive therapy (ESNM37) © NICE 2018. All rights reserved. Subject to Notice of rights (https (...) Guerrini R, Rosati A, Segieth J et al. (2013) A randomized phase III trial of adjunctive zonisamide in pedatric patients with partial epilepsy. Epilepsia 54: 1473–80 About this evidence summary 'Evidence summaries: new medicines' provide summaries of key evidence for selected new medicines, or for existing medicines with new indications or formulations, that are considered to be Partial seizures in children and young people with epilepsy: zonisamide as adjunctive therapy (ESNM37) © NICE 2018. All

2014 National Institute for Health and Clinical Excellence - Advice

16. Treatment gap for convulsive status epilepticus in resource-poor countries. Full Text available with Trip Pro

Treatment gap for convulsive status epilepticus in resource-poor countries. The magnitude of the treatment gap (TG) for convulsive status epilepticus (CSE) in resource-poor countries is unknown. Hospital-based cohort studies from developing countries revealed that the management of CSE was usually suboptimal due to lack of advanced diagnostic and treatment facilities, significant delay in patient's presentation at hospital, and shortages of essential antiepileptic drugs (AEDs). However (...) at the primary care level, but intravenous lorazepam was available only in four countries. Second-line AEDs were widely available at tertiary care hospitals, but not at primary care hospitals. Lack of second-line AEDs at primary care hospitals, significant delay in patient transportation to the hospital, shortages of intensive care unit facilities, and absence of trained physicians were important contributing factors to TG in Asia.Wiley Periodicals, Inc. © 2018 International League Against Epilepsy.

2018 Epilepsia

17. Childhood Convulsive Status Epilepticus Management In A Resource Limited Setting

Childhood Convulsive Status Epilepticus Management In A Resource Limited Setting Childhood Convulsive Status Epilepticus Management In A Resource Limited Setting - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding (...) more. Childhood Convulsive Status Epilepticus Management In A Resource Limited Setting The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03650270 Recruitment Status : Completed First Posted : August 28, 2018 Last Update Posted : August 28, 2018 Sponsor: University of Cape Town Information provided

2018 Clinical Trials

18. Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adolescence Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures

Study Completion Date : February 28, 2022 Resource links provided by the National Library of Medicine related topics: related topics: available for: Groups and Cohorts Go to Group/Cohort Intervention/treatment Fycompa-treated epilepsy participants Adolescent epilepsy participants with partial-onset seizures (with or without secondary generalized seizures) or primary generalized Tonic-clonic seizures who receive long-term treatment with Fycompa Drug: Fycompa The usual oral dosage for adults (...) Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adolescence Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adolescence Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures

2017 Clinical Trials

19. Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adult Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures

, 2021 Resource links provided by the National Library of Medicine related topics: related topics: available for: Groups and Cohorts Go to Group/Cohort Intervention/treatment Fycompa-treated epilepsy participants Adult epilepsy participants with partial-onset seizures (with or without secondary generalized seizures) or primary generalized Tonic-clonic seizures who receive long-term treatment with Fycompa Drug: Fycompa The usual oral dosage for adults and children 12 years of age or older is initially (...) Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adult Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adult Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures - Full Text

2017 Clinical Trials

20. Lactate Compared to Creatine Kinase as Diagnostic Marker in Generalized Epileptic Seizure

) analysis. Study Design Go to Layout table for study information Study Type : Observational Actual Enrollment : 85 participants Observational Model: Cohort Time Perspective: Prospective Official Title: Lactate Compared to Creatine Kinase as Diagnostic Marker in Generalized Epileptic Seizure Study Start Date : November 2015 Actual Primary Completion Date : August 2016 Actual Study Completion Date : August 2016 Resource links provided by the National Library of Medicine related topics: related topics (...) Lactate Compared to Creatine Kinase as Diagnostic Marker in Generalized Epileptic Seizure Lactate Compared to Creatine Kinase as Diagnostic Marker in Generalized Epileptic Seizure - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>